Clinical and PET Responses to Long-Term High-Dose Interferon-{alpha} Treatment Among Patients with Erdheim-Chester Disease

Conclusion: High-dose IFN-α treatment is a cost-effective option, especially for patients without CNS involvement. Single target lesion SUV elevation according to FDG-PET do not accurately demonstrate disease progression, but serial FDG-PET imaging effectively discriminate treatment response.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Cao, X., Niu, N., Sun, J., Cai, H., Wang, F.-d., Wang, Y.-n., Zhong, D.-r., Duan, M.-h., Zhou, D.-b., Li, J. Tags: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation Source Type: research